Biomarkers in biological fluids for dementia with Lewy bodies

CSF A 42 predicts early-onset dementia in Parkinson disease

(2014) G. Alves et al.   NEUROLOGY

Effects of Baseline CSF α-Synuclein on Regional Brain Atrophy Rates in Healthy Elders, Mild Cognitive Impairment and Alzheimer’s Disease

(2014) Niklas Mattsson et al.   PLoS One

Neuroimaging characteristics of dementia with Lewy bodies

(2014) Elijah Mak et al.   Alzheimers Research & Therapy

CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer’s disease

(2013) Jon B. Toledo et al.   ACTA NEUROPATHOLOGICA

Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias

(2013) Megan K. Herbert et al.   Alzheimers & Dementia

Evaluation of the Cerebrospinal Fluid Amyloid-�1-42/Amyloid-�1-40 Ratio Measured by Alpha-LISA to Distinguish Alzheimer's Disease from Other Dementia Disorders

(2013) Magdalena Nutu et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

Analysis of video-polysomnographic sleep findings in dementia with Lewy bodies

(2013) Michele Terzaghi et al.   MOVEMENT DISORDERS

Low CSF Levels of Both α-Synuclein and the α-Synuclein Cleaving Enzyme Neurosin in Patients with Synucleinopathy

(2013) Malin Wennström et al.   PLoS One

The Diagnostic Value of CSF α-Synuclein in the Differential Diagnosis of Dementia with Lewy Bodies vs. Normal Subjects and Patients with Alzheimer’s Disease

(2013) Elisabeth Kapaki et al.   PLoS One

Clinical and multimodal biomarker correlates of ADNI neuropathological findings

(2013) Jon B Toledo et al.   Acta Neuropathologica Communications

Cerebrospinal Fluid Levels ofβ-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia

(2012) Peder Buchhave   ARCHIVES OF GENERAL PSYCHIATRY

Neurobiology of cognitive impairment in Parkinson’s disease

(2012) Kurt A Jellinger   Expert Review of Neurotherapeutics

Brain amyloid and cognition in Lewy body diseases

(2012) Stephen N. Gomperts et al.   MOVEMENT DISORDERS

Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia

(2012) S. N. Gomperts et al.   NEUROLOGY

Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?

(2011) Y. Compta et al.   BRAIN

Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson's disease

(2011) Ivana Devic et al.   BRAIN

Different CSF β-amyloid processing in Alzheimer’s and Creutzfeldt–Jakob disease

(2011) Brit Mollenhauer et al.   JOURNAL OF NEURAL TRANSMISSION

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

(2010) Min Shi et al.   ANNALS OF NEUROLOGY

Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies

(2010) Brit Mollenhauer et al.   Biomarkers in Medicine

DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease

(2010) Zhen Hong et al.   BRAIN

New Insights into Biological Markers of Frontotemporal Lobar Degeneration Spectrum

(2010) Barbara Borroni et al.   CURRENT MEDICINAL CHEMISTRY

Tissue-specific Functions in the Fatty Acid-binding Protein Family

(2010) Judith Storch et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

CSF synuclein: adding to the biomarker footprint of dementia with Lewy bodies

(2010) B. Mollenhauer et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

CSF amyloid-  and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest study

(2010) G. Alves et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

CSF Aβ42and tau in Parkinson's disease with cognitive impairment

(2010) Thomas J. Montine et al.   MOVEMENT DISORDERS

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

(2010) Kaj Blennow et al.   Nature Reviews Neurology

Detection of elevated levels of  -synuclein oligomers in CSF from patients with Parkinson disease

(2010) T. Tokuda et al.   NEUROLOGY

[11C]PIB-, [18F]FDG-PET and MRI imaging in patients with Parkinson’s disease with and without dementia

(2010) Pekka Jokinen et al.   PARKINSONISM & RELATED DISORDERS

Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease

(2009) Yaroslau Compta et al.   MOVEMENT DISORDERS

Identification of Novel APP/Aβ Isoforms in Human Cerebrospinal Fluid

(2009) Erik Portelius et al.   Neurodegenerative Diseases

Reduced CSF CART in dementia with Lewy bodies

(2009) Kristofer Schultz et al.   NEUROSCIENCE LETTERS

EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up

(2008) L. Bonanni et al.   BRAIN

Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography

(2008) P Edison et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

CSF Mg and Ca as diagnostic markers for dementia with Lewy bodies

(2008) Fredrik Boström et al.   NEUROBIOLOGY OF AGING

Imaging amyloid deposition in Lewy body diseases

(2008) S. N. Gomperts et al.   NEUROLOGY